<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epidermal growth factor receptor is over-expressed in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and is the target for the <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi> <z:chebi fb="0" ids="49668">gefitinib</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>This receptor is also over-expressed in esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e>, specific <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> residing in the epidermal growth factor receptor tyrosine kinase in the activation loop and the glycine-rich P-loop, are responsible for an enhanced sensitivity toward <z:chebi fb="0" ids="49668">gefitinib</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed exons 19 and 21 coding for the receptor tyrosine kinase of the epidermal growth factor gene in 105 samples of esophageal (Barrett's) <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> by denaturing high-pressure liquid chromatography </plain></SENT>
<SENT sid="4" pm="."><plain>We found only one silent mutation in exon 19 of <z:chebi fb="1" ids="16708">adenine</z:chebi> to <z:chebi fb="1" ids="16235">guanine</z:chebi> in codon 754 leading to a substitution of K to K, the rest of the sample being <z:mp ids='MP_0002169'>wild-type</z:mp> genotype </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, mutations within the tyrosine kinase domain of EGFR associated with sensitivity of <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> patients to <z:chebi fb="0" ids="49668">gefitinib</z:chebi> are not present in esophageal (Barrett's) <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>